Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 plus SBRT in recurrent head and neck cancer
NCT04220775Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2020
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04220775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220775.